RxDoctor Payments Data

Dominee Ehrhardt, NP

Adult Health · Raleigh, NCNPI 1083020788

Payments from drug & device makers

$3,326in general payments, 2019–2025

Across 199 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$715
  • Novo Nordisk$560
  • Boehringer Ingelheim$438
  • Lilly USA, LLC$236
  • Pfizer$179
  • AstraZeneca$150
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,326100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,326 in reported general payments places this provider in the 85th percentile of 614 adult health providers in North Carolina.

See all adult health providers in North Carolina

Medicare billing

Part B allowed, 2024
$95,901
Medicare patients
318
Services billed
1,125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$131,019
JardianceEmpagliflozin87$119,136
TrulicityDulaglutide57$84,391
EliquisApixaban99$74,103
MounjaroTirzepatide47$72,401
JanuviaSitagliptin Phosphate44$64,641
Repatha SureclickEvolocumab55$63,252
FarxigaDapagliflozin Propanediol30$34,523
XareltoRivaroxaban27$32,781
MyrbetriqMirabegron36$30,936
Breo ElliptaFluticasone/Vilanterol35$28,966
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$19,664
TradjentaLinagliptin29$19,216
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$18,447
GemtesaVibegron18$13,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$236$156,792104 claims
Boehringer IngelheimJardiance, Tradjenta$438$138,352116 claims
Novo NordiskOzempic$560$131,01988 claims
PfizerEliquis$179$74,10399 claims
GSKBreo Ellipta, Anoro Ellipta, Trelegy Ellipta$133$67,07778 claims
AstraZenecaFarxiga$150$34,52330 claims
Astellas Pharma US IncMyrbetriq$21$30,93636 claims
Sumitomo Pharma America, Inc.Gemtesa$52$13,45518 claims
AbbVieSynthroid$715$3,48851 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 614 adult health providers in North Carolina.

Other adult health in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →